Ulcerative colitis approved drugs: Types and benefits

Ulcerative colitis (UC) is basically your immune system throwing a loud, messy tantrum in your colon.
The goal of treatment isn’t just to “feel less awful today” (though yes, please). Modern UC care aims for
deep remissionmeaning fewer symptoms, calmer inflammation on scopes, and a life that doesn’t revolve around
mapping every restroom like you’re planning a heist.

The good news: UC now has a growing menu of FDA-approved medicationsfrom classic anti-inflammatory
therapies to targeted biologics and oral “small molecules.” The better news: your gastroenterologist doesn’t
pick at random. The best drug is the one that matches your disease severity, where inflammation lives in your
colon, your medical history, and your lifestyle (because “infusion every 8 weeks” and “pill every day” are
very different vibes).

What “approved drugs” means (and why you should care)

When a medication is “approved” for UC, it means the U.S. Food and Drug Administration reviewed evidence that it
works for a specific UC situation (like inducing remission or maintaining it) and that the benefits outweigh risks
for the intended population. That doesn’t mean the drug is perfect, or perfect for you. It means the drug has
solid clinical-trial support and standardized labeling for UC.

You’ll also hear about medications that doctors use off-label (commonly in severe hospital flares).
Off-label use can still be evidence-based, but it’s different from FDA-labeled UC indications. This article focuses
mainly on FDA-approved UC drugs, and clearly labels other “sometimes used” options when helpful.

How doctors match UC drugs to your situation

UC treatment usually follows two big ideas:

• Induction: calm a flare and get you into remission.
• Maintenance: keep you there (without living on steroids, because that’s a bad deal long-term).

A simplified way many clinicians think about it:

• Mild UC (often limited symptoms, less extensive inflammation): start with 5-ASA therapies and targeted rectal meds if disease is near the rectum.
• Moderate to severe UC (frequent symptoms, bleeding, significant inflammation, or poor response to basics): step up to biologics or targeted oral therapies.
• Severe hospitalized flare: rapid control (usually IV steroids) and “rescue” therapy if needed.

The rest is personalization: previous medication response, infection risks, pregnancy plans, other autoimmune conditions,
insurance realities, and how much you hate needles (no judgment).

1) Aminosalicylates (5-ASA): the classic first-line anti-inflammatory option

Think of 5-ASAs as “local peacekeepers” for the colon lining. They’re commonly used for mild to moderate UC,
especially when inflammation is closer to the rectum or left side of the colon.

Common FDA-approved examples

• Mesalamine (multiple oral formulations; rectal suppositories/enemas depending on where inflammation is)
• Sulfasalazine (an older option; sometimes helpful if joint symptoms also show up)
• Balsalazide and olsalazine (other 5-ASA variations)

Key benefits

• Effective for mild to moderate UC, especially for symptom control and maintaining remission.
• Rectal 5-ASA can be extremely effective for proctitis or left-sided diseasebecause it goes exactly where the problem is.
• Often well-tolerated compared with stronger immune-suppressing drugs.

Real-life example

If you have ulcerative proctitis (inflammation mainly in the rectum), a rectal mesalamine suppository may work
better than “more powerful” meds that treat your whole bodybecause UC doesn’t need a flamethrower when a fire extinguisher
does the job.

2) Corticosteroids: fast flare control (not a long-term relationship)

Steroids are the emergency brake. They work quickly to reduce inflammationbut they’re not meant for long-term maintenance.
In UC care, the phrase “steroid-sparing” is basically a love language.

Systemic steroids (strong, fast, whole-body)

• Prednisone (oral)
• Methylprednisolone (often IV in the hospital)

Gut-targeted/“topical” steroids (more localized)

• Budesonide-MMX (an oral steroid designed to release in the colon; approved for mild to moderate active UC)
• Budesonide rectal foam (approved for mild to moderate distal UC)
• Hydrocortisone enemas/foams (often used for distal disease)

Key benefits

• Can rapidly reduce bleeding, urgency, and diarrhea during a flare.
• Bridge therapy while a slower maintenance medication ramps up.
• Gut-targeted budesonide options may reduce some systemic side effects compared with prednisone (still not “side-effect free,” though).

Tradeoffs to know

Steroids can cause mood changes, sleep issues, acne, increased blood sugar, higher infection risk, and bone loss with longer use.
So the plan is usually: use steroids to get control, then transition to a maintenance strategy.

3) Advanced therapies for moderate to severe UC: biologics and targeted small molecules

When UC is moderate to severeor when basic therapies don’t holddoctors often use treatments that target specific immune pathways.
These drugs can reduce inflammation more deeply and help achieve goals like mucosal healing and steroid-free remission.

Anti-TNF biologics: blocking a major inflammation signal

Tumor necrosis factor (TNF) is a key driver of inflammation. Anti-TNF drugs can be effective for inducing and maintaining remission,
and they’re also used as “rescue therapy” in some severe situations.

• Infliximab (IV infusion; includes biosimilars)
• Adalimumab (self-injection; includes biosimilars; approved for adults and certain pediatric UC)
• Golimumab (self-injection)

Benefits:

• Proven option for moderate to severe UC, including people who need a strong induction strategy.
• Often improves quality of life by reducing flares, bleeding, urgency, and fatigue.
• Biosimilars can lower costs and expand access (same target, highly similar performance).

Vedolizumab: a gut-selective biologic (the bouncer at the colon club)

Vedolizumab works differently: it helps block certain immune cells from traveling into gut tissue.
Because it’s gut-focused, many clinicians consider it a strong option when infection risk or systemic side effects are a concern.

Benefits:

• Effective for moderate to severe UC as induction and maintenance.
• Gut-selective mechanism may mean fewer whole-body immune effects compared with broader immunosuppressants.
• Flexible administration options depending on formulation and clinical plan.

Interleukin pathway biologics: targeting IL-12/23 or IL-23

Interleukins are immune “messenger proteins.” Blocking certain interleukins can reduce inflammation in UC with a targeted approach.

Ustekinumab (IL-12/23 blocker)

Ustekinumab targets IL-12 and IL-23 and is approved for moderate to severe UC in adults.

Benefits:

• Option for patients who have not responded well to other therapies.
• Maintenance dosing can be more spaced out than some other advanced therapies (depending on your regimen).

Newer IL-23–focused options (IL-23 “p19” targeting)

IL-23–specific drugs focus on a key inflammatory pathway in IBD. In the U.S., several IL-23–pathway therapies now have UC indications.

• Mirikizumab (brand: Omvoh) – approved for moderate to severe UC in adults; includes IV induction and subcutaneous maintenance, with newer maintenance convenience options.
• Risankizumab (brand: Skyrizi) – approved for moderate to severe UC in adults.
• Guselkumab (brand: Tremfya) – approved for moderate to severe UC in adults.

Benefits:

• Additional options for patients who didn’t respond to anti-TNF drugs or who need a different mechanism.
• May help achieve deeper healing targets (symptoms + endoscopic improvement).
• Some regimens allow at-home maintenance injections after induction.

Oral targeted small molecules: pills with a mission

These are not biologics (they’re not antibodies). They’re smaller compounds that target immune signaling inside cells.
The biggest “perk” is conveniencemany are oral. The biggest “catch” is that safety monitoring matters.

JAK inhibitors

• Tofacitinib (brand: Xeljanz) – an oral JAK inhibitor approved for moderate to severe UC in adults.
• Upadacitinib (brand: Rinvoq) – an oral selective JAK inhibitor approved for moderate to severe UC in adults (often after inadequate response/intolerance to certain biologics).

Benefits:

• Oral dosing and rapid onset for many patients.
• Effective option for some people with difficult-to-control moderate to severe UC.

Important safety note:

JAK inhibitors carry boxed warnings about serious risks (including serious infections and other major adverse events).
They require careful patient selection, screening, and monitoringthis is very much a “GI specialist + shared decision-making” zone.

S1P receptor modulators

• Ozanimod (brand: Zeposia) – an oral S1P receptor modulator approved for moderately to severely active UC in adults.
• Etrasimod (brand: Velsipity) – an oral S1P receptor modulator approved for moderately to severely active UC in adults.

Benefits:

• Oral dosing (no infusions, no injection training montage required).
• Targets immune cell trafficking and activity in a way that can reduce gut inflammation.
• Useful option for moderate to severe UC, including people who have tried other therapies.

Because S1P modulators can affect lymphocyte counts and other body systems, labels include recommended pre-treatment assessments and ongoing monitoring.

4) Maintenance convenience options: when “staying well” needs to fit real life

Maintenance therapy is where you win the long game. And the long game is easier when your plan is realistic.
Several FDA-approved UC therapies support at-home maintenance dosing after an induction phase.

Zymfentra: subcutaneous infliximab for maintenance

Zymfentra (infliximab-dyyb) is an FDA-approved subcutaneous formulation used for maintenance in adults with UC
(and Crohn’s disease). It’s designed for patients who have already been induced and stabilized on IV infliximab, then switch to at-home injections.

Benefit: fewer infusion-center visits while staying on an infliximab-based strategy.

Switching and combination therapy (brief, but important)

If a drug works at first and then loses effect, your clinician may:

• Optimize dose/timing (sometimes guided by drug levels for certain biologics).
• Switch within a class (e.g., one anti-TNF to another) or switch mechanisms (anti-TNF → IL-23 → S1P, etc.).
• Use combination therapy in select cases to improve response (balanced against infection risk).

The benefits that matter most (beyond fewer bathroom sprints)

When an FDA-approved UC drug is doing its job, benefits often stack up like dominoesin a good way:

• Symptom relief: less bleeding, urgency, diarrhea, and abdominal pain.
• Fewer flares: longer stretches of stability.
• Steroid-free control: less need for prednisone “rescue missions.”
• Mucosal healing: better outcomes over time (your colon lining gets a break).
• Reduced complications: fewer hospitalizations and, for some patients, lower surgery risk.
• Quality of life: better sleep, energy, school/work attendance, and social life.

Safety checklist: tests, vaccines, and monitoring

With advanced therapies, the “benefit” side of the equation is only half the story. Smart monitoring helps keep treatment safer.
Typical steps may include:

• Infection screening before biologics and certain oral agents (commonly tuberculosis and hepatitis B).
• Baseline labs (such as CBC and liver tests) and follow-ups depending on the medication class.
• Vaccine planning before immunosuppressive therapy when possible (especially because live vaccines are generally avoided during significant immunosuppression).
• Ongoing check-ins to track symptoms, labs, and inflammation markers (sometimes stool markers or repeat scopes, depending on your plan).

If this sounds like a lot, remember: the goal is to prevent big problems early. Monitoring is basically the “check engine” light for treatmentannoying,
but wildly preferable to breakdowns on the highway.

Questions to ask your gastroenterologist

• Is my UC mild, moderate, or severeand what’s that based on (symptoms, labs, colonoscopy, imaging)?
• Is this medication for induction, maintenance, or both?
• How will we measure successsymptoms only, or also stool tests/colonoscopy targets?
• What side effects should I watch for, and what requires urgent medical attention?
• What vaccines or screening tests should I get before starting?
• If this drug doesn’t work, what’s our next step (optimize dose, switch class, etc.)?
• What are the realistic costs and support programs, and are biosimilars an option?

Conclusion

“Ulcerative colitis approved drugs” isn’t one categoryit’s a toolbox. Mild disease often responds well to 5-ASAs and localized rectal therapies.
Steroids can help stop a flare quickly, but they’re meant to be a short-term bridge. For moderate to severe UC, FDA-approved biologics and targeted oral therapies
(anti-TNFs, vedolizumab, ustekinumab, IL-23 drugs like Omvoh/Skyrizi/Tremfya, and oral agents like JAK inhibitors or S1P modulators) can help achieve deeper remission
and protect long-term health.

The best plan is the one that gets you to remission and keeps you theresafely, sustainably, and with monitoring that matches the medication’s risk profile.
If you’re choosing among options, talk through your goals (symptom control, fewer flares, convenience, pregnancy plans, safety concerns) and let your care team tailor the strategy.

Real-world experiences: what living with UC meds can feel like (the part brochures don’t always mention)

People rarely describe UC treatment as “one pill, one miracle, the end.” More often, it’s a processlike finding the right pair of jeans, except the jeans are medications
and the fitting room is your immune system. Here are common experiences patients report when navigating FDA-approved UC drugs, framed in a practical, expectations-setting way.

1) The trial-and-adjust phase is normal. Many patients start with 5-ASAs, then discover they need a step-up approach.
That’s not failureit’s information. UC can change over time, and a medication that worked for years may need optimization later. Doctors often adjust dose, route
(adding rectal therapy to oral meds), or switch mechanisms (for example, anti-TNF to IL-23) based on response.

2) “Feeling better” and “healing” aren’t always the same day. Symptom improvement can happen before inflammation is fully controlledor the reverse.
Some people notice urgency improves quickly, while fatigue lingers. Others feel okay but still have inflammation on a scope, which is why clinicians talk about treat-to-target
and sometimes use stool markers or follow-up colonoscopy to confirm deeper remission.

3) Administration style becomes a lifestyle decision. Infusions can feel like a scheduled pit stop: you bring headphones, snacks, and a plan for the afternoon.
At-home injections can feel empowering (“I’ve got this”) or intimidating (“Why does this pen look so confident?”). Oral therapies are convenient, but they often come with
more lab monitoring. Many patients end up choosing a regimen that fits work/school schedules, travel, and mental bandwidthnot just the strongest option on paper.

4) Steroids are a love-hate relationship. People often describe prednisone as effective but chaotic: symptoms improve, but sleep gets weird, appetite spikes,
and emotions may run hotter than usual. That’s why many patients celebrate getting off steroids and onto a maintenance plan that keeps them stable without that rollercoaster.

5) The “logistics layer” is real. Prior authorizations, specialty pharmacies, infusion center scheduling, copay cards, and step therapy can be frustrating.
Many patients say the biggest help is having a clinic that’s proactive with paperwork and a personal checklist:
confirm shipment dates, store medication correctly, schedule labs, and keep a note of symptoms (even quick bullet points).

6) Monitoring can feel like homework, but it pays off. Lab checks and screening tests can be annoyinguntil they catch something early.
People who do best long-term often treat monitoring as part of the medication, not an optional add-on. It’s also common to plan vaccines and preventive care before starting
immunosuppressive drugs so you’re not scrambling later.

7) The biggest “benefit” is getting your life back. Patients talk about the moment they stop scouting bathrooms, stop declining plans, and start trusting their bodies again.
That return of confidenceeating without fear, traveling without panic, making it through a school day or a long shiftis why finding the right FDA-approved UC therapy matters.

If you’re early in treatment or switching meds, it can feel like a lot. But UC care has expanded dramatically in the last decade.
The odds of finding a workable, effective plan are better than everespecially when you and your GI team treat it like a partnership with clear targets, realistic timelines, and good follow-through.